Key Points
- Sujata Tyagi Dayal, a director, sold 13,761 shares of Emergent Biosolutions on May 1 at an average price of $8.40 for $115,592.40, reducing her stake by 12.04% to 100,563 shares under a pre-arranged Rule 10b5-1 plan.
- Emergent reported a Q1 surprise with EPS of $0.21 versus a consensus loss of ($0.25) and revenue of $156.1M (vs. $145M), while the stock trades around $8.50 with a market cap of about $439M and a 12‑month range of $4.71–$14.06.
- Analyst views are mixed — the consensus rating is a Hold with an average target of $12.00 — and institutional investors own roughly 78.4% of the shares.
Emergent Biosolutions Inc. (NYSE:EBS - Get Free Report) Director Sujata Tyagi Dayal sold 13,761 shares of the company's stock in a transaction on Friday, May 1st. The shares were sold at an average price of $8.40, for a total transaction of $115,592.40. Following the completion of the transaction, the director owned 100,563 shares of the company's stock, valued at $844,729.20. This trade represents a 12.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Emergent Biosolutions Price Performance
Shares of EBS stock opened at $8.51 on Tuesday. The company has a market capitalization of $439.20 million, a PE ratio of -30.38 and a beta of 2.33. The firm has a fifty day simple moving average of $8.54 and a 200-day simple moving average of $10.30. The company has a current ratio of 4.29, a quick ratio of 2.08 and a debt-to-equity ratio of 1.10. Emergent Biosolutions Inc. has a twelve month low of $4.71 and a twelve month high of $14.06.
Emergent Biosolutions (NYSE:EBS - Get Free Report) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.46. The business had revenue of $156.10 million during the quarter, compared to the consensus estimate of $145.00 million. Emergent Biosolutions had a negative net margin of 1.27% and a positive return on equity of 10.76%.
Wall Street Analyst Weigh In
EBS has been the subject of several analyst reports. Weiss Ratings downgraded shares of Emergent Biosolutions from a "sell (d+)" rating to a "sell (d)" rating in a research note on Monday, April 27th. HC Wainwright decreased their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Monday, March 9th. Finally, Wall Street Zen downgraded shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a research note on Sunday, March 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $12.00.
Read Our Latest Report on EBS
Institutional Trading of Emergent Biosolutions
Institutional investors and hedge funds have recently modified their holdings of the business. Torren Management LLC acquired a new stake in shares of Emergent Biosolutions during the fourth quarter worth $37,000. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Emergent Biosolutions during the fourth quarter worth $45,000. Legal & General Group Plc acquired a new stake in shares of Emergent Biosolutions during the second quarter worth $31,000. Farther Finance Advisors LLC raised its holdings in shares of Emergent Biosolutions by 361.3% during the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company's stock worth $76,000 after purchasing an additional 4,827 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Emergent Biosolutions during the second quarter worth $53,000. 78.40% of the stock is owned by institutional investors and hedge funds.
Emergent Biosolutions Company Profile
(
Get Free Report)
Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.
Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
